Walter Greenblatt, a veteran life science focused investment banker, raises seed capital and early institutional funding for fast-growing life science startups including WuXi Pharmatech (NYSE: WX), MedAvante, Advanced BioHealing, Callidus Biopharma and others in a variety of therapeutic areas. In addition to raising early-stage capital, he closes M&A and business development transactions for clients developing therapeutics, medical devices and pharmaceutical services. The life science focused, Princeton NJ-based firm he founded, Walter Greenblatt & Associates (“WGA”), works on an exclusive basis with a small number of clients, generally working over an extended period to raise a staged series of increasingly large capital rounds. The firm’s success rate in raising capital for its clients exceeds 90%.
WGA has raised $83 million in very early stage equity for life science startups. Investors include high net worth individuals, family offices and life science focused venture capital firms. To date, the investors in WGA rounds have realized cash returns from those rounds exceeding $515 million, or 6.25X, an IRR of over 66%. Over half of the WGA clients that have not yet generated returns for investors are continuing to build towards a liquidity event. Walter Greenblatt is an experienced entrepreneur and “hands-on” operating executive himself. Prior to founding Walter Greenblatt & Associates, he founded, grew and sold a profitable business over an eleven-year period. Before that, he was with Bain & Company. He received his MBA Harvard Business School (with Distinction) after graduating from Yale (summa cum laude) and receiving a Masters in Economics (with First Class Honours) from Balliol College, Oxford University.